Effect of Xihuang Capsules on liver function and cellular immune function in patients with primary liver cancer after transcatheter arterial chemoembolization
LIU Lina1 QIU Xingdong1 LI Xianchao1 ZHANG Guojing2▲
1.Department of Oncology, Wenzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medicine University, Zhejiang Province, Wenzhou 325000, China;
2. Department of Oncology, Wenzhou Geriatric Hospital, Zhejiang Province, Wenzhou 325000, China
Abstract：Objective To observe the effects of Xihuang Capsules on liver function and cellular immunity in patients with primary liver cancer after transcatheter arterial chemoembolization (TACE). Methods From November 2020 to June 2022, 80 patients with primary liver cancer who underwent TACE treatment in the Department of Oncology, Wenzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medicine University were selected as the research objects, all patients had liver function damage. They were divided into experimental group and control group by random number table method, with 40 cases in each group. The control group were given two courses (14 days as a course) conventional liver protection treatment. The experimental group were given Xihuang Capsules adjuvant therapy on the basis of the control group. Liver function indicators including alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBil), and direct bilirubin were contrasted before and after treatment. T lymphocyte subsets(CD4+, CD8+, CD4+/CD8+) and natural killer (NK) cells levels were collected and contrasted before and after intervention. Clinical symptoms were contrasted before and after treatment. Results Before treatment, there were no significant difference in ALT, AST, TBil, and direct bilirubin between the two groups (P＞0.05). After treatment, the levels of CD4+, CD4+/CD8+ and NK cells in experimental group were higher than before treatment, while CD8+ was lower than before treatment, and the levels of CD4+, CD4+/CD8+ and NK cells in experimental group were higher than those in control group (P＜0.05), and CD8+ cells in experimental group were lower than those in control group (P＜0.05). After treatment, the levels of CD4+/CD8+ and NK cells in control group were higher than those before treatment (P＜0.05). There was no significant difference in clinical symptoms (loss of appetite, gastrointestinal reaction and fatigue) between the two groups (P＞0.05). Conclusion Xihuang Capsules has obvious anti-tumor effect, improves liver function, and has significant immune regulation ability for tumor patients, which is worthy of further study.
刘利娜1 裘兴栋1 李献超1 章国晶2▲. 西黄胶囊对原发性肝癌肝动脉化疗栓塞术后患者肝功能和细胞免疫功能的影响 [J]. 中国医药导报, 2023, 20(17): 119-122.
LIU Lina1 QIU Xingdong1 LI Xianchao1 ZHANG Guojing2▲. Effect of Xihuang Capsules on liver function and cellular immune function in patients with primary liver cancer after transcatheter arterial chemoembolization. 中国医药导报, 2023, 20(17): 119-122.
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China [J]. CA Cancer J Clin，2016，66（2）：115.
[2] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[3] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范（2019年版）[J].中华肝脏病杂志，2020，（2）：112-128.
[4] Papatheodoridi M，Tam paki M，Lok AS，et al. Risk of HBV reactivation during therapies for HCC：A system atic review [J]. Hepatology，2022，75（5）：1257-1274.
[5] 谢晴晴，孙一帆.肝细胞生长因子与肿瘤发生发展的关系进展[J].中国医药导报，2021，18（33）：45-48，67.
[6] 李晨晨，张亚玲，郑玉玲.中药治疗原发性肝癌TACE术后综合征有效性及安全性系统评价[J].海南医学院学报，2022，28（18）：1398-1412.
[7] 马素平，陈欣菊，陈晓琦.原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识[J].临床肝胆病杂志，2021， 37（7）：1545-1549.
[8] 杨海宁，樊庆胜，刘福全，等.中医调肝理脾法防治肝癌栓塞术后综合征的临床观察[J].中华介入放射学电子杂志，2021，9（1）：20-24.
[9] 国家卫生和计划生育委员会.原发性肝癌诊疗规范（2017年版）[J].消化肿瘤杂志（电子版），2017，9（2）：213-228.
[10] 中华中医药学会.肿瘤中医诊疗指南[J].中医药导报，2008，14（12）：36.
[11] Lu J，Zhang XP，Zhong BY，et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis：comparing east and west [J]. Lancet Gastroenterol Hepatol，2019，4（9）：721-730.
[12] 魏明芳，申明，任宏飞，等.肝细胞癌患者反刍性沉思的影响因素[J].中国医药导报，2022，19（2）：108-111.
[13] 卢冬彦，叶小卫.参芪化瘀方联合经导管动脉化疗栓塞治疗原发性肝癌患者的效果[J].中国医药导报，2023， 20（5）：98-101，110.
[14] 陈明，丁恩.阿帕替尼联合经动脉导管灌注化疗栓塞术治疗原发性肝癌的临床效果及对患者免疫功能的影响[J].中国医药，2022，17（6）：871-875.
[15] 吴晓峰，刘一纬，张慧，等.不同巴塞罗那临床肝癌Kinki分期在肝癌根治术中的应用价值[J].中华消化外科杂志，2020，19（12）：1266-1272.
[16] 彭昭宣，朱晓宁，彭孟云，等.原发性肝癌TACE术后的并发症及治疗[J].中国医药科学，2023，13（5）：53-56.
[17] Lu J，Zhao M，Arai Y，et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma：consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology （ISMIO） [J]. Hepatobiliary Surg Nutr，2021，10（5）：661- 671.
[18] 吴姗姗，王振常，吕艳杭，等.柔肝化纤解毒方治疗原发性肝癌TACE术后综合征的临床疗效观察[J].中华中医药杂志，2021，36（5）：3038-3041.
[19] 李朋娟，赖丽，李红阁.加减龙胆泻肝汤对原发性肝癌TACE术后栓塞综合征患者肝功能和生活质量的影响[J].广州中医药大学学报，2021，38（5）：876-879.
[20] 赵延军，单宇鹏.复方斑蝥胶囊对原发性肝癌患者介入治疗后细胞免疫功能的影响[J].陕西中医，2018，39（1）：77-79.
[21] 高磊磊，秦帅鑫，陈威，等.TACE联合RFA治疗中期原发性肝癌的疗效及对患者血清GP73、AFP和AFP-L3水平的影响[J].临床和实验医学杂志，2021，20（13）：1388-1391.
[22] 李新叶，苏亮，徐钰，等.西黄丸调节肿瘤微环境中Treg细胞PI3K/AKT通路的抗肿瘤作用机制研究[J].世界科学技术-中医药现代化，2018，20（1）：49-54.
[23] 邵萌，周太成，殷志新，等.西黄丸的抗肿瘤作用及临床应用研究进展[J].国际药学研究杂志，2017，44（6）：504-509.
[24] Wang X，Meng JY，He SF. Xihuang Pill induces mesenchymalepithelial transition and inhibits loss of apical-basal polarity in colorectal cancer cell through regulating ZEB1- SCRIB loop [J]. Chin J Integr Med，2014，20（10）：751-757.
[25] 吴晓泉，朱力平.西黄丸联合肝动脉化疗栓塞术对晚期肝癌患者生存预后的影响分析[J].江西医药，2016，51（8）：774-775.
[26] 杜旦锋，郭丽，盛丽娜，等.西黄丸抗肿瘤转移作用及其机制研究[J].中药材，2018，8（8）：1995-1998.
[27] 周云娣.西黄丸辅助治疗晚期原发性肝癌效果观察[J].临床合理用药，2020，13（2）：73-75.
[28] 任庆，熊锐华，何玉婵，等.西黄胶囊联合CIK细胞治疗晚期鼻咽癌临床研究[J].现代中西医结合杂志，2021， 30（6）：584-587，592.
[29] 华琼博，牟海波，郭勇.水木两滋汤加味对肝肾阴亏型中晚期原发性肝癌患者TACE后的疗效及其外周血T淋巴细胞亚群的影响[J].中国现代医生，2021，59（5）：129-132.
京公网安备 11010502046598号